Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model by Yakob, Laith et al.
RESEARCH ARTICLE Open Access
Clostridium difficile exposure as an insidious
source of infection in healthcare settings:
an epidemiological model
Laith Yakob1*, Thomas V Riley2, David L Paterson3 and Archie CA Clements1
Abstract
Background: Clostridium difficile is the leading cause of infectious diarrhea in hospitalized patients. Its epidemiology
has shifted in recent years from almost exclusively infecting elderly patients in whom the gut microbiota has been
disturbed by antimicrobials, to now also infecting individuals of all age groups with no recent antimicrobial use.
Methods: A stochastic mathematical model was constructed to simulate the modern epidemiology of C. difficile in
a healthcare setting, and, to compare the efficacies of interventions.
Results: Both the rate of colonization and the incidence of symptomatic disease in hospital inpatients were
insensitive to antimicrobial stewardship and to the prescription of probiotics to expedite healthy gut microbiota
recovery, suggesting these to be ineffective interventions to limit transmission. Comparatively, improving hygiene
and sanitation and reducing average length of stay more effectively reduced infection rates. Although the majority
of new colonization events are a result of within-hospital ward exposure, simulations demonstrate the importance
of imported cases with new admissions.
Conclusions: By analyzing a wide range of screening sensitivities, we identify a previously ignored source of
pathogen importation: although capturing all asymptomatic as well as symptomatic introductions, individuals who
are exposed but not yet colonized will be missed by even a perfectly sensitive screen on admission. Empirical
studies to measure the duration of this latent period of infection will be critical to assessing C. difficile control
strategies. Moreover, identifying the extent to which the exposed category of individual contributes to pathogen
importation should be explicitly considered for all infections relevant to healthcare settings.
Background
Clostridium difficile is a Gram-positive, toxin-producing
anaerobic bacterium. Worldwide, it is the leading cause
of infectious diarrhea in hospitalized patients. The inci-
dence and severity of C. difficile infection (CDI) varies
considerably among studied populations but the general
trend shows an increase in recent decades [1-3], with a
higher proportion of CDI patients undergoing colectomy
and dying [4,5]. The disease is currently estimated to
cost $800 million per year in US acute care facilities [6].
Previously, persistently disturbed intestinal microbiota,
usually as a result of antimicrobials, was considered a
prerequisite of the disease. However, recent studies have
demonstrated severe cases occurring in groups that were
previously assumed to be low-risk, including pregnant
women, children and people with no recent exposure to
antimicrobials [7,8], indicating either a changing epi-
demiology or more testing in these groups [9].
There is increasing evidence for a potentially import-
ant role of asymptomatic carriage in the epidemiology of
CDI [10], with increasing rates recorded within
healthcare settings [11] and for the wider community
[12,13]. Hospital rooms occupied by asymptomatic pa-
tients can have very high rates of contamination (29%)
[14]. The dissociation between symptoms and infectivity
was recently corroborated by a prospective clinical study
in which 60% of patients still had skin contamination
following resolution of diarrhea in CDI patients, and
37% continued to shed spores in their stool [15]. Car-
riers have been implicated in the global spread of hyper-
* Correspondence: laith.yakob@uq.edu.au
1School of Population Health, The University of Queensland, Brisbane,
Australia
Full list of author information is available at the end of the article
© 2013 Yakob et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Yakob et al. BMC Infectious Diseases 2013, 13:376
http://www.biomedcentral.com/1471-2334/13/376
virulent strains such as ribotype 027 which is believed to
have caused over 2000 fatalities during the 2003–4 out-
break in Quebec, Canada [16]. Increased incidence, se-
verity of disease associated with endemic strains and
frequency of outbreaks emphasize the urgency for im-
proved epidemiological understanding. To this end, we
construct the most comprehensive epidemiological
model of CDI transmission reported to date and use it
to compare the efficacies of key interventions.
Surprisingly, there are only three modeling studies de-
scribing the mechanism of CDI transmission, each pro-
viding insight but with important limitations. The first
mathematical model of CDI by Starr and colleagues [17]
ignored asymptomatic carriage, a major potential source
of infection for this disease [11,18]. While this omission
was rectified by the authors in a subsequent study [19],
differential rates of progression to symptomatic disease
between patients who were and who were not taking an-
timicrobials [20] were not accounted for. The third mod-
eling study [21], developed by Lanzas and colleagues,
did not allow for symptomatic disease in patients who
were not on antimicrobials thereby overlooking a grow-
ing body of research showing high incidence rates in
previously healthy individuals to be a key feature of C.
difficile epidemiology [22,23]. Although parsimony
should always be a goal of epidemiological models, the
inclusion of greater biological realism in our simulations
highlights a hitherto unreported and potentially signifi-
cant source of infection. We use this stochastic model to
assess and compare the efficacies of several interventions
to reduce infection transmission. We discuss the signifi-
cance of our findings to infectious disease transmission
within healthcare settings in general as well as specific-
ally to the epidemiology of CDI.
Methods
The C. difficile pathogen
C. difficile is transmitted via the fecal-oral route. The in-
fectious dose is small and the bacterium is capable of
producing spores which can remain viable for years in
the environment [24]. There has been a recent sugges-
tion of inhalation of spores potentially providing a sec-
ondary mode of transmission [25,26], but this is unlikely
to contribute significantly to the disease’s epidemiology.
On ingestion, the pathogen colonizes the gut and the
host typically sheds bacteria in their stool within two
weeks.
A significant proportion of infections is asymptomatic,
with a spectrum of symptoms of varying severity experi-
enced by the remainder [14,27]. These symptoms in-
clude diarrhea, fever and abdominal pain and can result
in toxic megacolon and death. Reasons for the develop-
ment of symptomatic infection are incompletely under-
stood but the risk factor most commonly associated with
this progression is the disruption of normal gut micro-
biota by antimicrobials [28]. As a consequence of
disrupted gut microbiota and lack of local immunity, the
treatment of symptomatic infection with antimicrobials
is met with high relapse rates in patients who do not
successfully clear infection, as well as high reinfection
rates [29]. Our model is the first that allows for treated
individuals to return back to asymptomatically infected,
exposed or uncolonized states to reflect the fact that
treatment success is so variable. Following recent evi-
dence of an increasing trend in colonization and disease
in individuals who have not recently received antimicro-
bials [8], our model allows for the development of CDI
without antibiotic involvement.
Epidemiological model parameterization
Patients in a hospital with 1000 beds were simulated for
1 year. Individuals were stratified according to infection
status (Unexposed, Exposed, Colonized or Diseased) and
whether or not they were currently taking antimicrobials
(or had taken antimicrobials within the last 3 months).
Exposed, colonized and diseased patients all harbor the
pathogen; colonized and diseased patients contribute to
transmission, but only diseased patients exhibit symp-
toms. The overall structure of the model is described in
Figure 1. One novel component of our study is the in-
corporation of an ‘Exposed’ class of individuals which
explicitly allows for the fact that individuals who are not
colonized on admission may subsequently become colo-
nized regardless of within-hospital exposure. The epi-
demiological consequences of this addition are discussed
fully after the analysis.
Average length of stay was assumed to be 6 days,
reflecting rates that are typical of the US, Europe and
Australia [30]. Patients could be admitted in any of the
seven possible states but only discharged if they were
not suffering from symptomatic disease. The proportion
of new admissions that was taking (or had recently
taken) antimicrobials was assumed to be 25% and the
rates of antimicrobial prescription assumed that 50% of
the hospital inpatients were currently on antimicrobials
(or had taken them in the previous 3 months) [31,32].
Recovery of gut microbiota following cessation of anti-
microbial treatment was assumed to take 3 months [33].
New admissions were assumed to perfectly balance dis-
charges, resulting in a constant population size that ex-
perienced frequency-dependent transmission. This is
typical for the epidemiological modeling of human infec-
tious diseases [34].
After a period of 5 days, exposed individuals became
asymptomatically colonized [35]. For patients on antimi-
crobials, progression to symptomatic disease took a fur-
ther 5 days [20]. Patients not on antimicrobials were
assumed to be five-times less likely to progress to
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symptomatic disease [20]. Cure rate following treatment,
which took 10 days [36], was assumed to be 80% [37],
with the remaining treated patients returning to the ex-
posed category. The symptoms of 33% of patients with
CDI self-resolved [38] and 2% of symptomatic CDI pa-
tients died [20]. Table 1 summarizes the model parame-
ters and definitions with associated cited studies.
Mathematical model construction
Ordinary differential equations were constructed to
reflect the biology of infection as parsimoniously as
possible (Additional file 1). Traditionally, the basic
reproduction number, R0, is used to estimate transmis-
sion potential of an infectious disease. R0 is a useful
metric for estimating outbreak thresholds and is there-
fore of relevance in estimating risk of epidemic strains
introduced into fully susceptible (disease-free) popula-
tions. The stable endemicity of C. difficile within
healthcare settings represents a significant departure
from a disease-free population. Moreover, R0 no longer
quantifies risk nor discriminates between high levels and
low levels of transmission when constant imports of
pathogen are accounted for in healthcare settings [39].
Therefore, we present our results of control simulations
in terms of the incidence of symptomatic disease and
the ratio of colonized patients discharged from hospital
relative to patients colonized on admission. An advan-
tage of these measures of intervention efficacy is that
they can be directly measured.
Because the simulated population is small, infection
dynamics are more likely to be governed by stochastic
processes. Therefore, the ordinary differential equations
were converted into a stochastic simulation system
based on Gillespie’s direct method [40]. This method of
simulation accounts for continuous time but discrete
state space whereby the probability of conversion from
one state (e.g., Exposed) to another (e.g., Colonized) is
determined by the associate rate of the ordinary differen-
tial equation system. There are 15 possible epidemio-
logical state transitions in this system and they are
summarized in Table 2. The table shows the transfer of
individuals from one epidemiological compartment
(“-1”) to another (“+1”).
This stochastic model was used to compare the effi-
cacy of four different control measures in reducing the
rate of colonization within the hospital as well as the
Figure 1 Compartmental design of epidemiological model for Clostridium difficile. Individuals are either ‘U’nexposed, ‘E’xposed, ‘C’olonized
or ‘D’iseased and are increasingly ‘vul’nerable when they have taken antimicrobials (‘Ab’). Patients of all epidemiological states can be admitted
but only discharged if not symptomatic.
Table 1 Epidemiological model symbology and parameterization
Parameter Definition Value (,Vul) Reference
λ Recovery of gut microbiota (day-1) 0.011 33
α Antibiotic treatment (day-1) 0.11 31,32
β Exposure (day-1) Full range SIM
η Dev into asympt infectious (day-1) 0.2,0.2 35
θ Dev symptomatic CDI (day-1) 0.04,0.2 20
ρ CDI treatment (day-1) 0.1 36
σ Treatment failure (prop.) 0.2 37
ζ Self-resolving symptoms (prop.) 0.33 38
μ CDI case fatality rate (prop.) 0.02 20
κ Hospital discharge (day-1) 0.17 30
ε Hospital admission (proportion) 0.75,0.25 31,32
Q Quarantined CDI ‘0’ yes, ‘1’ no n/a
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incidence of symptomatic CDI. These controls were 1)
reducing the rate of antimicrobial prescription in order
to minimize the proportion of patients with heightened
vulnerability to symptomatic disease, 2) reducing the
level of environmental contamination and improving
hand hygiene, 3) administering probiotics to expedite
the restoration of healthy gut microbiota, and, 4) the re-
duction of average length of stay of inpatients.
The importance of asymptomatic patients in infection
transmission is a topic that has received a lot of recent
interest [10,11,41,42]. Despite this, the incubation periods
for C. difficile are less well defined than for other patho-
gens [9]. Simulating infection dynamics across a wide
range of incubation periods, we assessed the applicability
of screening for asymptomatic, as well as symptomatic,
admissions. Recent developments in commercially-
available PCR screening technology have provided a sensi-
tive (~90%) tool for rapidly detecting (~2 h) colonization
with C. difficile [43]. Therefore, we gauged the utility of
this screen as a further method of intervention under the
assumption that hospitals have the facilities to segregate
colonized (both asymptomatic and symptomatic) and
non-colonized patients.
Results and discussion
The temporal output from a typical stochastic simula-
tion run, using baseline parameterization and in the ab-
sence of intervention is shown in Figure 2. The top
panel shows the percentage of colonized individuals
discharged compared with the percentage of colonized
admissions. Average colonization prevalence on admis-
sion was 4.0% (st. dev. 2.0) which closely matches a re-
cent Canadian study that measured asymptomatic
admission prevalence of 4.4% in 6 hospitals in Quebec
2006–2007 [20]. We could not find clinical studies
measuring the prevalence of colonization on discharge
to directly corroborate our simulated values. However,
in our study, colonization and length of stay are inde-
pendent variables and so prevalence in discharged pa-
tients is representative of inpatient prevalence. Hospital
inpatient prevalence of endemic C. difficile varies a
Table 2 Epidemiological state transitions of the event-driven, stochastic model
Event Transition probability State change
Antibiotic treatment of uncolonized individual αUδt U-1, Uv+1
exposed individual αEδt E-1, Ev+1
colonized individual αCδt C-1, Cv+1
Gut microbiota recovery of uncolonized individual λUvδt Uv-1, U+1
exposed individual λEvδt Ev-1, E+1
colonized individual λCvδt Cv-1, C+1
Exposure of individual without recent Ab use β[(C+Cv+DQ)U/N]δt U-1, E+1
individual with recent Ab use β[(C+Cv+DQ)Uv/N]δt Uv-1, Ev+1
Colonization of individual without recent Ab use ηEδt E-1, C+1
individual with recent Ab use ηEvδt Ev-1, Cv+1
Symptoms develop in indiv. without recent Ab use θCδt C-1, D+1
individual with recent Ab use θvCvδt Cv-1, D+1
Symptoms resolve ζDδt D-1, Cv+1
Full clearance following treatment (1-σ)ρDδt D-1, Uv+1
Treatment does not result in full clearance σρDδt D-1, Ev+1
Figure 2 A typical simulation using baseline model
parameterization. Subplots show the percentage of Clostridium
difficile colonized patients who are admitted and discharged (top),
the incidence of symptomatic disease (middle) and the proportional
distribution of inpatient infection status (bottom). Stochastic (Direct
Gillespie algorithm) simulations are run for a hospital with 1000 beds
whereby newly admitted patients perfectly balance
discharged individuals.
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great deal over time and between different locations,
but our average colonization prevalence of 30% (st. dev.
5.6%) falls within the range described in the clinical lit-
erature [44].
The middle panel of Figure 2 shows the incidence of
symptomatic C. difficile infection which averages 2.8
cases per 1000 hospital bed days (st. dev. 4.2), also
within the range described in the most comprehensive
pan-European survey [45]. The very high rates of
underreporting that are known to occur for this patho-
gen, especially in younger patients who have less severe
symptoms, suggest that the true prevalence of infection
lies towards the top-end of estimates [46]. The bottom
panel shows the proportional distribution of the epi-
demiological states of hospital inpatients in which the
ratio of total (vulnerable or otherwise) Unexposed: Ex-
posed: Colonized: Diseased patients is 0.45: 0.26: 0.24:
0.05. Importantly, our baseline parameterization using
the most up-to-date data available for this pathogen sug-
gests that there are as many individuals in the ‘Exposed’
category as in the ‘Colonized’ category.
Figure 3 shows the sensitivity of two different outputs
(ratio of colonized patients discharged compared with
on admission, and, the incidence of symptomatic CDI),
to the four model parameters pertaining to control –
namely, the rate of antimicrobial prescription, the trans-
mission coefficient (reduced by improved hygiene and
sanitation), gut microbiota recovery rate (expedited with
probiotics) and average length of stay. Projections from
the model reinforce the clinical evidence supporting a
reduced length of stay [47,48] and infection control
[49-51] as effective methods for attenuating the spread
of C. difficile. While there is reassuring agreement be-
tween our model projections and clinical records of
intervention efficacy, there is also an important disparity
worth noting. Several recent studies have suggested anti-
microbial stewardship to be an effective method of redu-
cing the rate of CDI in hospitals [52-55]. However, these
include studies that examined stewardship in conjunc-
tion with infection control procedures [54,55], thereby
obscuring the efficacy of reduced prescription rates
alone. They also include studies that found either bor-
derline significant reduction in CDI (P=0.04, [53]) or no
statistical significance through a reduction in either
high-risk drugs or total antimicrobial usage in healthcare
settings (respectively, P=0.0597 and P=0.0823, [52]).
Therefore, the conflicting evidence for CDI reduction
through antimicrobial stewardship is in keeping with a
small effect size, as demonstrated by our simulations.
Infection rates were also insensitive to increased gut
microbiota recovery promoted by probiotics. Cautious
interpretation of this result is urged because while we
found the overall influence that this treatment has on
population-level transmission dynamics to be minimal, it
does not necessarily negate the individual-level health
benefits of probiotics.
Comparatively much greater returns were achieved by
reducing the length of stay and through improved hygiene
(respectively, bottom-right and top-right panel Figure 3).
Halving the average inpatient length of stay yielded almost
a 3-fold reduction in the colonized ratio of discharged
compared with admitted patients. Additionally, a 10-fold
decrease in CDI incidence was theoretically possible
through improved hygiene and sanitation practices. How-
ever, even in this scenario whereby complete elimination
of within-ward exposure was achieved (β=0), more pa-
tients left the hospital colonized than when they arrived.
This is due to the expedited progression of disease
resulting from antimicrobials, suggesting that stewardship
might come into play as a more influential control tool
once initial efforts have already eliminated ward-based
transmission.
A thorough sensitivity analysis of model input parame-
ters (see Additional file 2) demonstrates the robustness
of our results pertaining to infection control. However,
there are several limitations of this study that will re-
quire additional development and refinement. The life-
course of the pathogen is incompletely understood. Our
model structure assumes that all individuals who be-
come symptomatic must first pass through a phase of
shedding the pathogen asymptomatically. This follows
Figure 3 The effects of different control measures on
Clostridium difficile in the simulated hospital. The ratio of
patients colonized with C. difficile when discharged compared to
new admissions (left Y axis, points) are shown along with associated
incidence of symptomatic disease per 1000 hospital bed days (right
Y axis, crosses) across a wide range of the four tested control
measures: reducing antimicrobial prescription (top-left), improved
sanitation and hygiene (top-right), administering pro-biotics
(bottom-left) and reducing the average length of stay (bottom-
right). Each point is the average value of a 1-year simulation.
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on from the very comprehensive epidemiological study
carried out by Loo and coauthors in which the time to
developing symptomatic disease was measured to be
twice that for developing asymptomatic colonization
[20]. An alternative interpretation of this finding would
be that the individuals who develop symptomatic infec-
tion never pass through a phase of asymptomatic shed-
ding, but, instead, have a delayed progression of
colonization. However, this would imply that successful
colonization within patients that develop symptomatic
disease is somehow delayed. In the absence of definitive
evidence, therefore, our assumption seems more likely.
Another limitation of the study is the assumption that
asymptomatic shedders contribute equivalently to trans-
mission as symptomatically infected individuals. While
symptomatic disease involves a greater bacterial load,
asymptomatic shedding would not prompt the same
level of cautiousness in hygiene practices. Ascertaining
the relative contributions of both category of individual
will be a difficult, but important, issue to reconcile. Once
good, reproducible data become available on this differ-
ence, the model can easily be adjusted to incorporate the
additional information. A further limitation is the lack of
consideration for healthcare professionals (and, also,
hospital visitors) as vectors of infection – again, some-
thing that will require further development when the
epidemiological data become available. Greater complex-
ity can be iteratively incorporated into the framework
presented here to explore additional risk factors includ-
ing patient age as well as underlying co-morbidities and
patient immune status. Future directions for this work
also include assessing the integration of control tools.
Integrated control has been strategized with mathemat-
ical models for a number of infectious diseases including
sexually transmitted infections [56,57], vector-borne dis-
eases [58-60], newly emerging infections and pathogenic
bioterrorism attacks [61,62]. However, research into stra-
tegic combinations of healthcare-acquired infection con-
trol methods is underdeveloped.
Finally, we measured the sensitivity of the colonization
ratio and the incidence of CDI on the pathogen’s incuba-
tion period – the C. difficile life history parameter of
greatest uncertainty [9]. Intuitively, for shorter incuba-
tion periods, the colonization ratio increased along with
CDI incidence (Figure 4). This is because longer incuba-
tion periods delay the rate at which a pathogen can
spread between individuals. Remarkably, however, infec-
tion rates were extremely insensitive to screening sensi-
tivity. Even where screening was 100% sensitive (current
leading rapid screen sensitivity is ~90%) [43], little im-
pact on infection rates was achieved by the segregation
of all colonized admissions from non-colonized inpa-
tients. Recent studies have suggested that a large propor-
tion of patients colonized with C. difficile in healthcare
settings was likely exposed to the pathogen before they
were admitted [11,21,41,42]. These authors thereby attri-
bute a substantial role of asymptomatic individuals on
the importation of infection. In this analysis, by screen-
ing and subsequently isolating both asymptomatic and
symptomatic patients from the non-colonized inpatients,
we have eliminated these sources of infection and un-
covered a previously ignored and potentially important
source of C. difficile in healthcare settings: new admis-
sions who have been exposed to the pathogen but not
yet colonized.
Conclusions
Even a perfect screening test giving immediate results
for all new admissions will fail to detect the carriage
of C. difficile into the hospital by patients. Although
obtaining good estimates of the incubation period has
proven particularly difficult [9], it will be critical to
uncovering the extent to which the exposed category
of individuals influences the epidemiology of CDI.
This finding is not only relevant to C. difficile epi-
demiology, but to any pathogen that can be undetect-
ably transported by exposed individuals.
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Figure 4 The effects of screening on Clostridium difficile in the
simulated hospital. The ratio of patients that are colonized with C.
difficile when discharged relative to on admission (left) are shown
along with the associated incidence in symptomatic CDI per 1000
hospital bed days (right). Even highly sensitive screening (Y axis) can
do little to impact either of these epidemiological outcomes.
However, time to colonization (X axis), a component of the
pathogen’s life course for which data is absent, is highly influential
in its epidemiology.
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